Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
Equillium, Inc. (EQ)
Last equillium, inc. earnings: 3/26 04:07 pm
Check Earnings Report
Company Research
Source: Business Wire
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited, in collaboration with Equillium, has initiated a Phase 2 clinical study of itolizumab in patients with ulcerative colitis (UC).The Phase 2 double-blinded placebo-controlled clinical study is evaluating the safety and efficacy of itolizumab for biologics-naïve patients with moderate to severe active UC, where patients are randomized 1:1:1 to receive a fixed dose of 140 mg of itolizumab, adalimumab, or placebo every two weeks for a 12-week treatment period, with adalimumab non-responders able to cross over to itolizumab. The study is expected to enroll up to 90 patients in multiple clinical trial sites in India. The trial design and initiation have been a collaborative effort, with help from the gastroenterologist community and leading global clinica
Show less
Read more
Impact Snapshot
Event Time:
EQ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EQ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EQ alerts
High impacting Equillium, Inc. news events
Weekly update
A roundup of the hottest topics
EQ
News
- Equillium, Inc. (NASDAQ: EQ) had its price target lowered by analysts at Stifel Nicolaus from $12.00 to $7.00.MarketBeat
- Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development UpdatesBusiness Wire
- Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease ConferenceBusiness Wire
- Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTRBusiness Wire
- Equillium, Inc. (NASDAQ: EQ) had its price target lowered by analysts at SVB Leerink LLC from $12.00 to $7.00. They now have an "outperform" rating on the stock.MarketBeat
EQ
Earnings
- 3/23/23 - Beat
EQ
Analyst Actions
- 3/24/23 - Stifel
EQ
Sec Filings
- 3/23/23 - Form 10-K
- 3/23/23 - Form 8-K
- 3/3/23 - Form SC
- EQ's page on the SEC website